Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...